Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

“Trick Cigar Blows Man’s Head Off”

In a new online exhibition, The University of Alabama Center for the Study of Tobacco and Society examines tobacco in the tabloids. 

This exhibition is drawn from the Center’s collection of supermarket tabloid newspapers with stories about smoking in the 40 years following the publication in 1964 of the Surgeon General’s Report on Smoking and Health—when the few early anti-smoking messages by the American Cancer Society and other health organizations were being drowned out by the torrent of cigarette ads on TV (until 1971), on billboards, at sports events, and in newspapers and magazines. 

Tabloid headline reads: "Cigarette Company Targets Babies".
Tabloid headline reads: "Militant anti-smoking group blamed after… TRICK CIGAR BLOWS MAN’S HEAD OFF! ‘He took two puffs and then –BOOM!’ says restaurant manager”.
Tabloid headline reads: "Owners forced to buy cigarettes for pooches addicted to smoking. Dogs born with intense cravings for nicotine, say stunned vets."
Tabloid headline reads: "New York mom of 6-year-old does slow burn. 'If my daughter can't smoke in school - I'll sue'"
Tabloid headline reads: "Cigarettes cured my cancer"
Tabloid headline reads: "Discovered at last: Cancer-proof cigarettes!"

Because of the tabloids’ large circulation and their readers’ lower educational attainment compared to the major newsweeklies TIME, Newsweek, and U.S. News & World Report — which were heavily dependent on cigarette advertising and minimized their coverage of smoking and cancer — these publications could have played a life-saving role in educating the public about the devastating health consequences of cigarette smoking. 

Instead, they, too, passed the buck.

Read more on the Cancer History Project. 

Related articles by the Center for the Study of Tobacco and Society


This column features the latest posts to the Cancer History Project by our growing list of contributors. 

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study. 
Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login